Sponsored By

Bausch & Lomb Withdraws Eye Supplement LawsuitBausch & Lomb Withdraws Eye Supplement Lawsuit

March 14, 2005

1 Min Read
Bausch & Lomb Withdraws Eye Supplement Lawsuit

ROCHESTER, N.Y.--Bausch & Lomb (B&L) withdrew the lawsuit it filed in U.S. District Court on May 8, which originally alleged Waltham, Mass.-based Inverness Medical Innovations and its subsidiary, Freehold, N.J.-based IVC Industries, manufacture and distribute vitamin supplements that infringe upon patent rights tied to the formula behind B&Ls Ocuvite® PreserVision eye supplements. According to B&L, it received notification from Inverness declaring neither it nor IVC distribute or manufacture certain eye private label eye supplements that infringe upon the patent rights. B&L noted the dispute was quickly clarified due to a thorough internal review and prompt, direct communication by Inverness.

B&L developed the formula in conjunction with the National Eye Institute (NEI) and holds worldwide patent rights under a license agreement with the National Institutes of Health (NIH). The landmark NEI Age-Related Eye Disease Study (AREDS) showed supplementation with antioxidant vitamins (C, E and beta-carotene) plus zinc (as supplied by B&L) lowered risk of age-related macular degeneration (AMD) and its associated vision loss, but had no effect on development or progression of cataract (Arch Ophthamol. 119:1417-36, 2001).

Inverness (www.invernessmedical.com) and IVC offer OptiZinc and Eye Vitamin plus Lutein in their private label manufacturing line.

Subscribe and receive the latest insights on the healthy food and beverage industry.
Join 47,000+ members. Yes, it's completely free.

You May Also Like